Trial Profile
Post-Marketing Surveillance of Fycompa in Korean Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy; Generalised seizures; Seizures; Tonic-clonic epilepsy
- Focus Adverse reactions
- Sponsors Eisai Korea
- 02 Aug 2021 Status changed from recruiting to completed.
- 16 Jun 2021 Planned number of patients changed from 2426 to 3000.
- 03 Apr 2020 Planned primary completion date changed from 30 Jul 2021 to 30 Jun 2021.